Gynecologic Oncology

Ritu Salani, MD, MBA, discusses the current state of biomarker testing in cervical cancer.

Yale Cancer Center scientists have found that combining the targeted drug trastuzumab with chemotherapy significantly improves survival rates for women with a rare, aggressive form of endometrial cancer.

Bradley J. Monk, MD, FACS, FACOG, discusses the utility of tisotumab vedotin in recurrent cervical cancer.

The antibody-drug conjugate tisotumab vedotin induced clinically meaningful and durable responses in patients who have relapsed or progressed on or after previous treatment for recurrent or metastatic cervical cancer.

The field of gynecologic oncology gained a number of important updates at the 2020 ASCO Virtual Scientific Program. As part of the ASCO Direct Highlights webcast, Jubilee Brown, MD, provided insight on key trials that were presented at the program.

Endometrial cancer tumor types are traditionally categorized through a combination of histologic molecular subtyping and clinical staging; however, the incorporation of new diagnostic algorithms may have clinical implications for treatment.

David O'Malley, MD, discusses the utility of mirvetuximab soravtansine in ovarian cancer.

R. Wendel Naumann, MD, discusses the early results reported with STRO-002, the hope for this agent in the ovarian cancer space, and the next steps for this research.

Pembrolizumab demonstrated modest clinical activity in patients with advanced recurrent ovarian cancer.

Brian M. Slomovitz, MD, discusses sequencing strategies for endometrial cancer.

Ursula A. Matulonis, MD, discusses final data from the phase 2 KEYNOTE-100 trial with pembrolizumab (Keytruda) in advanced recurrent ovarian cancer.

The combination of nivolumab plus ipilimumab was found to induce a superior response rate and longer progression-free survival compared with nivolumab alone in patients with persistent or recurrent epithelial ovarian cancer.

Konstantin Zakashansky, MD, gynecologic oncologist and associate professor of Obstetrics, Gynecology and Reproductive Science at Mount Sinai Health System, discusses repeat exposure to PARP inhibition in patients with platinum-sensitive, relapsed ovarian cancer.

Joyce F. Liu, MD, MPH, discusses findings from a phase 2 study with the Wee1 inhibitor adavosertib in patients with recurrent uterine serous carcinoma.

Gestational trophoblastic tumors (GTTs) that resist chemotherapy can be treated with frontline avelumab, making avelumab the first immunotherapy to show efficacy in treating patients with GTT, according to findings from a cohort of the ongoing phase 2 TROPHIMMUN trial.

Maintenance niraparib improved progression-free survival in Chinese patients with recurrent ovarian cancer who were in a complete or partial response to platinum-based chemotherapy, meeting the primary end point of the phase 3 NORA study.

Brian M. Slomovitz, MD, explaines the need to determine optimal sequencing strategies in endometrial cancer.

Brian M. Slomovitz, MD, explaines the need to determine optimal sequencing strategies in endometrial cancer.

Shannon N. Westin, MD, MPH, discusses novel targets in endometrial cancer.

Thomas Herzog, MD, discusses the FDA approval of olaparib plus bevacizumab for the frontline maintenance treatment of patients with homologous recombination deficiency–positive ovarian cancer.

The anti­–folate receptor alpha antibody-drug conjugate STRO-002 showed early clinical promise in patients with advanced ovarian cancer.

The vaccine BVAC-C demonstrated durable antitumor activity in patients recurrent cervical cancer.

Shannon N. Westin, MD, MPH, FACOG, discusses future directions in endometrial cancer.

Ritu Salani, MD, discusses the evolving role of biomarker development and testing in cervical cancer.

A reduction in patient-reported symptomatic adverse events was observed with intensity-modulated radiotherapy compared with standard radiotherapy in patients with cervical or endometrial cancer, whereas no difference was observed with regard to clinician-reported AEs.